Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Puma Biotechnology (PBYI) Non-Current Assets (2017 - 2025)

Puma Biotechnology (PBYI) has disclosed Non-Current Assets for 9 consecutive years, with $53.6 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Non-Current Assets fell 18.36% year-over-year to $53.6 million, compared with a TTM value of $234.9 million through Dec 2025, down 12.34%, and an annual FY2025 reading of $53.6 million, down 18.36% over the prior year.
  • Non-Current Assets was $53.6 million for Q4 2025 at Puma Biotechnology, down from $59.3 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $94.9 million in Q1 2021 and bottomed at $53.6 million in Q4 2025.
  • Average Non-Current Assets over 5 years is $75.6 million, with a median of $77.3 million recorded in 2022.
  • The sharpest move saw Non-Current Assets soared 41.95% in 2021, then decreased 18.36% in 2025.
  • Year by year, Non-Current Assets stood at $86.6 million in 2021, then increased by 1.4% to $87.8 million in 2022, then fell by 15.31% to $74.3 million in 2023, then decreased by 11.66% to $65.7 million in 2024, then fell by 18.36% to $53.6 million in 2025.
  • Business Quant data shows Non-Current Assets for PBYI at $53.6 million in Q4 2025, $59.3 million in Q3 2025, and $58.3 million in Q2 2025.